Revvity/$RVTY
Revvity shares rise after management highlighted AI-driven demand, a growing life-sciences backlog and improving preclinical spending at the Morgan Stanley healthcare conference.
12 hours agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Revvity
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
- Ticker
- $RVTY
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 11,000
- Headquarters
- Waltham, United States
- Website
- www.revvity.com
Revvity Metrics
BasicAdvanced
$14B
61.34
$2.09
1.09
$0.28
0.22%
Price and volume
Market cap
$14B
Beta
1.09
52-week high
$133.00
52-week low
$81.22
Average daily volume
1.6M
Dividend rate
$0.28
Financial strength
Current ratio
1.8
Quick ratio
1.357
Long term debt to equity
0.383
Total debt to equity
0.462
Dividend payout ratio (TTM)
13.36%
Interest coverage (TTM)
4.93%
Profitability
EBITDA (TTM)
875.832
Gross margin (TTM)
54.98%
Net profit margin (TTM)
8.16%
Operating margin (TTM)
15.92%
Effective tax rate (TTM)
8.97%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
2.37%
Return on equity (TTM)
3.21%
Valuation
Price to earnings (TTM)
61.341
Price to revenue (TTM)
4.986
Price to book
1.98
Price to tangible book (TTM)
-8.94
Price to free cash flow (TTM)
26.013
Free cash flow yield (TTM)
3.84%
Free cash flow per share (TTM)
4.94
Dividend yield (TTM)
0.22%
Forward dividend yield
0.22%
Growth
Revenue change (TTM)
4.05%
Earnings per share change (TTM)
-11.50%
3-year revenue growth (CAGR)
0.87%
10-year revenue growth (CAGR)
3.58%
3-year earnings per share growth (CAGR)
-31.42%
10-year earnings per share growth (CAGR)
-0.01%
What the Analysts think about Revvity
Analyst ratings (Buy, Hold, Sell) for Revvity stock.
Analyst projections of the future price of Revvity stock.
Bulls say / Bears say
Revvity beat second-quarter expectations and raised 2026 guidance to $2.83 billion-$2.86 billion of revenue, 4%-5% organic growth and $5.30-$5.40 of adjusted EPS. Diagnostics grew 11% organically and adjusted operating margin improved, suggesting the recovery is gaining traction. (Reuters, BioSpace)
AI-led drug discovery is creating a potential new source of demand: management said AI-related work is generating incremental orders, while Revvity has added native AI capabilities to its Signals software platform. If adoption continues, higher instrument use could also drive follow-on reagent and software sales. (Reuters, Business Wire)
The planned acquisition of Human Cell Design adds human pancreatic beta-cell models that can be combined with Revvity’s assays, screening and analysis tools. This gives the Life Sciences division a differentiated route into diabetes, obesity and GLP-1 drug research. (BioSpace)
Life Sciences remains weak: Q2 organic revenue fell 3%, with Signals software revenue down about 20% due partly to contract timing. A continued software slump could offset Diagnostics growth and delay the broader recovery. (Reuters)
The adjusted profit beat was not all operational: $16 million of tariff refunds supplied a meaningful part of the upside, while favourable tax timing will reverse in the fourth quarter. GAAP operating margin still fell to 12.2% as selling, general and administrative and restructuring costs rose. (TradingKey, Equibles)
2026 guidance is presented excluding China Immunodiagnostics, which represented about 6% of 2025 revenue, and the sale may not close until the end of 2027 pending approvals. Investors therefore face a long portfolio transition and must distinguish reported growth from pro forma growth. (StockTitan, BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Revvity Financial Performance
Revenues and expenses
Revvity Earnings Performance
Company profitability
Upcoming events
Revvity News
AllArticlesVideos
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
Business Wire7 days ago
Revvity to Present at Upcoming Investor Conferences
Business Wire1 month ago
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing
Business Wire1 month ago
Funds containing Revvity
AllUSDEURGBP
Fund name | Fund size | $RVTY weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.39% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.39% |
iShares Healthcare Innovation£DRDR | £1B | 1.39% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.23% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.21% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.